Therapeutic efficacy of Benzoxazinorifamycins against Mycobacterium avium complex infection induced in mice and rabbits.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Therapeutic efficacy of Benzoxazinorifamycins against Mycobacterium avium complex infection induced in mice and rabbits.

Abstr Annu Meet Am Soc Microbiol. 1991 May 5-9;91:152 (abstract no. U-59). Unique Identifier : AIDSLINE ASM91/0100292
Saito H; Tomioka H; Sato K; Hidaka T; Shimane Medical University, Izumo, Japan.

Abstract: Newly synthesized rifamycin derivatives, benzoxazinorifamycins (KRMs; Kanegafuchi Chemical Ind. Co., Osaka, Japan), have a markedly improved in vitro activity against various mycobacteria including M.avium complex (MAC), and their MICs against most strains were more than 64 times lower than those of RFP. In this study, we examined in vivo activity of the KRMs against MAC infections induced in mice and rabbits. When BALB/c mice infected iv with M.intracellulare N-260 strain were given each of five KRMs suspended in arabic gum-Tween 80 solution by lavage at doses of 0.2 and 0.4 mg/mouse, daily, 6 times per week, from day 1, for up to 8 weeks after infection, the incidence of gross lung lesions was completely inhibited, accompanied by 2-3 order decrease in the number of CFU of the organisms in the lungs, as compared to untreated animals. When NZW rabbits infected iv with M.avium N-425 strain were given KRM-1648, which exhibited most superior efficacy in the murine experimental infections, at doses of 25 and 50 mg/Kg in the same protocol as in the case of mice, extension of the survival time and 1-3 order decrease in the number of CFU of the organisms in the lungs, liver, spleen and kidneys were noted. Further, MAC-induced bactermia, as seen in MAC-associated AIDS patients, was also nearly completely suppressed by the KRM-treatment.

Keywords: Animal Blood/MICROBIOLOGY Colony Count, Microbial Kidney/MICROBIOLOGY Liver/MICROBIOLOGY Lung/MICROBIOLOGY Mice Microbial Sensitivity Tests Mycobacterium avium Complex/DRUG EFFECTS Mycobacterium avium-intracellulare Infection/*DRUG THERAPY Rabbits Rifamycins/*THERAPEUTIC USE Spleen/MICROBIOLOGY ABSTRACT
920830
M9281073

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .